SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it was added to the Russell 2000 and Russell 3000 Indexes as part of the 2021 Russell indexes annual reconstitution that took effect after the market close on June 25, 2021.

The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its indexes primarily by objective, market-capitalization rankings and style attributes. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes.

“We are pleased to be added to the Russell indexes,” said Greg Perry, Chief Financial Officer of Finch Therapeutics. “Finch’s inclusion will help broaden our exposure to the investment community as we continue to advance the development of several novel microbiome therapeutics, with our lead product candidate positioned to enter a Phase 3 clinical trial and two other innovative development programs slated to enter the clinic this year.”